Hepatocellular Carcinoma (HCC) Treatment: Massive R&D Investments and Rising Cases of HCC to Spur Market Growth

A recent research report by MarkNtel Advisors has revealed that the Global Hepatocellular Carcinoma (HCC) Market is set to record around 10.20% CAGR during 2022-27. The rising patient pool of HCC due to the rapidly increasing elderly population levels worldwide, coupled with growing lifestyle disorders, are the prime aspects projected to drive the market in the forecast years. In addition, substantial R&D investments in discovering more effective HCC therapeutics, backed by the increasing number of clinical trials being conducted by various biopharma firms, are other prominent factors propelling the market growth.

FDA, PMDA, & EMA, among other regulatory agencies worldwide, are providing huge incentives, as well as fast drug approvals to biopharma companies for developing orphan drugs for rare diseases. The combination of PD- 1 or PDL- 1 with multikinase inhibitors, anti-VEGF drugs, or CTLA- 4 inhibitors is being offered to patients with late-stage HCC. Consequently, the mounting prevalence of liver cancer globally is another prominent aspect generating new avenues for the Hepatocellular Carcinoma (HCC) Market in the coming years.

For A Complete Understanding of This Report's [Summary + TOC]] Structure, Request A Free PDF of The Study's Report - https://www.marknteladvisors.com/query/request-sample/hepatocellular-carcinoma-hcc-market.html

Targeted Therapies hold a Prominent Share of the Hepatocellular Carcinoma (HCC) Market

Sorafenib & Lenvatinib are the two SOC (Standard of Care) targeted therapy drugs that currently dominate the Global Hepatocellular Carcinoma (HCC) Market. Of both, Sorafenib, an oral bi-aryl urea that inhibits multiple cell surface & downstream kinases involved in tumor progression, is a preferred systematic therapy for advanced HCC in Asia-Pacific, the Americas, & Europe. It owes to improved OS (overall success) rates in patients and mild to moderate severity of toxicities like diarrhea, fatigue, & hand-foot skin reactions. Nevertheless, the FDA-approved combination of Avastin (bevacizumab) & Tecentriq (atezolizumab) as the first-line treatment for patients suffering from metastatic or unresectable hepatocellular carcinoma has displayed enhanced efficacy & safety compared to kinase inhibitors, owing to which it would attain a larger share of the Global Hepatocellular Carcinoma (HCC) Market in the coming years.

With Substantial R&D Investments in Finding Effective Therapeutics for HCC, Asia-Pacific is set to Record Significant Market Growth

The rising incidence of HBV & HCV, the rapidly growing elderly population levels, and significantly increasing alcohol consumption are driving the Asia-Pacific Hepatocellular Carcinoma (HCC) Market. In addition, various government initiatives toward spreading awareness among people of the importance & availability of early detection of such diseases and the growing adoption of more effective & accurate diagnostic procedures for HCC, especially in India & China, are other notable factors anticipated to stimulate the regional market growth in the forecast years. Moreover, the declining prices of diagnostics solutions, remarkable developments in the healthcare sector, the booming medical tourism in China, and massive R&D investments by biopharma companies for discovering cost-effective HCC treatments would further propel the market expansion during 2022-27.

To View the Comprehensive Benchmark for The Entire Research Study, Click Here - https://www.marknteladvisors.com/research-library/hepatocellular-carcinoma-hcc-market.html

Competitive Landscape

The key players in the Global Hepatocellular Carcinoma (HCC) Market include Amgen Inc., AstraZeneca PLC, Bayer AG, BeiGene, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, & Pfizer Inc.

Key Questions Answered in the Research Report

-What are the current & future trends in the Global Hepatocellular Carcinoma (HCC) Market?

-How has the industry been evolving in terms of geography & product adoption?

-How has the competition been shaping across various regions, followed by their comparative factorial indexing?

-What are the key growth drivers & challenges for the Global Hepatocellular Carcinoma (HCC) Market?

-What are the customer orientation, purchase behavior, & expectations from the leading players in the Global Hepatocellular Carcinoma (HCC) Market?

To Inquire Further or Share Any Questions About This Report, Click Here - https://www.marknteladvisors.com/query/talk-to-our-consultant/hepatocellular-carcinoma-hcc-market.html

Market Segmentation:

-By Diagnosis (Blood Tests (AFP (Alfa-Fetoprotein), LFT (Liver Function Test)), Hepatic Angiography, Liver Biopsy, Laparoscopy, Others (MRI, CT scan, etc.))

-By Treatment (Surgery (Hepatectomy, Liver Transplant), Radiation Therapy, Chemotherapy (Cisplatin, Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), Doxorubicin (pegylated liposomal doxorubicin), 5-fluorouracil (5-FU)), Targeted Drug Therapy (Kinase Inhibitors (Sorafenib, Lenvatinib, Regorafenib (Stivarga), Cabozantinib (Cabometyx)), Monoclonal Antibodies (Bevacizumab (Avastin), Ramucirumab (Cyramza))), Immunotherapy (Atezolizumab (Tecentriq), Pembrolizumab (Keytruda), Nivolumab (Opdivo), Ipilimumab (Yervoy)))

-By End-User (Hospitals, Cancer Centers, Others (Ambulatory Surgery Centers, etc.))

-By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific)

-By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia)

More Latest Market Study Report By MarkNtel Advisors

https://www.marketwatch.com/press-release/a-deeper-look-into-the-regional-trends-of-the-elevator-and-escalator-market-2023-01-04

https://www.marketwatch.com/press-release/aircraft-hangar-equipment-market-a-look-of-the-latest-trends-and-opportunity-2023-01-04?mod=search_headline

https://www.marketwatch.com/press-release/exploring-the-drivers-of-growth-in-the-cloud-kitchen-market-2023-01-04?mod=search_headline

https://www.marketwatch.com/press-release/the-introduction-of-ai-in-the-fintech-industry-2023-01-06

https://www.marketwatch.com/press-release/predicting-the-future-of-construction-equipment-ce-market-in-india-a-comprehensive-guide-2023-01-06

Contact Us:
MarkNtel Advisors LLP
India:- +91 120 4278433
Canada:- +1 604 800 2671
E-mail: - sales@marknteladvisors.com

MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.

Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.

This release was published on openPR.